This bill stops the Department of Health and Human Services — including the Food and Drug Administration — from treating pregnancy as an illness for purposes of approving abortion drugs under FDA’s drug-approval authority and for imposing or maintaining risk evaluation and mitigation strategies (REMS). It then declares null and void any approval that relied on treating pregnancy as an illness, explicitly naming the current approval of mifepristone.
If enacted, the measure would remove federal approval status from any medication the agency approved on that legal premise, creating immediate regulatory and legal consequences for manufacturers, distributors, and clinicians who rely on FDA approval to market and supply medication abortion.
At a Glance
What It Does
The bill bars HHS/FDA from treating pregnancy as an illness in two specific regulatory capacities: approvals under 21 U.S.C. §355 and REMS under §355–1. It also retroactively nullifies any approvals that depended on that characterization, including the approval of mifepristone in effect the day before enactment.
Who It Affects
The prohibition directly affects FDA’s regulatory determinations, manufacturers and distributors of medication-abortion products, pharmacies and clinicians who dispense or prescribe those drugs, and state and federal enforcement officials responsible for illegal drug distribution under the FDCA.
Why It Matters
The proposal replaces a scientific/clinical classification used in FDA decision-making with a statutory rule that collapses the agency’s basis for authorizing a widely used therapeutic; that shift would instantly change the legal status of medication abortion and test the boundaries between Congress’s power to set statutory standards and FDA’s science-based regulation.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
The bill inserts a single, categorical rule into federal law: HHS and the FDA must not treat pregnancy as an illness when deciding whether to approve or to require REMS for what the bill calls an "abortion drug." By targeting both section 505 approvals and section 505–1 REMS authority, the draft removes two of the principal levers FDA uses to authorize, label, and control access to prescription medicines.
Beyond barring future determinations, the statute reaches backward. It declares that any approval that 'relied in whole or in part' on treating pregnancy as an illness is void, and it names the approval of mifepristone as an example.
In practice, voiding an FDA approval means the drug would no longer have the federal safety-and-efficacy authorization that permits interstate marketing and prescription under the FDCA; distribution of an unapproved drug can run afoul of 21 U.S.C. §331 and related enforcement provisions.The bill contains no definition of "abortion drug," no phase-in period, and no transitional safety structure. That silence forces immediate questions about how manufacturers can legally supply previously approved products, how pharmacies should respond, and whether states or federal officers must remove products from distribution.
It also places FDA science judgments under a statutory prohibition that substitutes a value-laden legal premise (pregnancy is not an illness) for the agency’s clinical determinations, creating friction between statutory direction and the agency’s traditional regulatory role.
The Five Things You Need to Know
The bill forbids HHS/FDA from treating pregnancy as an illness when approving drugs under 21 U.S.C. §355 and when imposing or keeping REMS under §355–1.
It retroactively nullifies any drug approval that "relied in whole or in part" on treating pregnancy as an illness, which the text says includes the approval of mifepristone in effect the day before enactment.
The statute does not define "abortion drug," nor does it establish a transition period or safety exceptions for drugs that would lose approved status.
Removing FDA approval would make distribution and interstate shipment of those drugs vulnerable to FDCA prohibitions on unapproved drugs, exposing manufacturers, distributors, and dispensers to enforcement risk.
The bill addresses both approval and REMS authority, so it removes not only the basis for marketing the drug but also the agency’s statutory tool for imposing controlled-access safety conditions.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
Provides the act’s name: "Pregnancy Is Not an Illness Act of 2025." This is purely a caption, but the phrasing signals the statute’s substantive premise and will shape statutory interpretation disputes about the legislative intent behind the prohibition.
Prohibition on treating pregnancy as an illness for approvals and REMS
Directs HHS and the FDA not to treat pregnancy as an illness for the specific purposes of approving abortion drugs under FDCA §505 and for imposing or maintaining REMS under §505–1. Practically, this strips the agency of the ability to rely on clinical characterizations that view pregnancy-related conditions as illnesses when making those two statutory determinations; it does not by its terms alter other FDA authorities not mentioned in the clause.
Nullification of prior approvals that relied on the disallowed treatment
Declares void any approval that 'relied in whole or in part' on treating pregnancy as an illness. The operative legal consequence of nullification is removal of the FDCA-approved status that permits interstate marketing and normal prescribing; absent a lawful approval, such products could be treated as unapproved new drugs under the FDCA, opening the door to enforcement actions.
Definition-like clause and explicit reference to mifepristone
Explains what the bill means by a 'prohibited approval' and explicitly states that the approval of mifepristone on the day before enactment is included. The express callout of a currently approved product signals congressional intent to reach specific marketed therapies and narrows interpretive disputes about whether the new prohibition applies retroactively to existing approvals.
This bill is one of many.
Codify tracks hundreds of bills on Healthcare across all five countries.
Explore Healthcare in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- Anti-abortion advocacy organizations and state officials seeking to restrict medication abortion: the statute provides a clear federal legal basis to challenge FDA approvals and to press for removal of medication-abortion products from interstate commerce.
- Members of Congress and policymakers who prioritize statutory constraints on FDA’s regulatory classifications: the bill converts a clinical characterization into a statutory prohibition that aligns FDA practice with their policy goals.
- Entities that refuse to dispense or stock medication abortion for conscientious or policy reasons: they gain a stronger legal environment if approvals and REMS that facilitated wide distribution are removed.
Who Bears the Cost
- Manufacturers of mifepristone and other medication-abortion products: they would lose federal approval status, disrupting marketing authorizations, supply contracts, and potential investments in development and litigation costs to defend approval status.
- Pharmacies, clinicians, and health systems that currently prescribe or dispense medication abortion: they face immediate compliance uncertainty, potential liability for handling an unapproved drug, and clinical disruptions for patients who rely on these therapies.
- Patients seeking medication abortion and clinicians providing outpatient reproductive-care services: loss of approval can reduce availability, increase logistical barriers, and push care into more complex clinical settings or out-of-state channels.
- FDA and HHS administrations: the agencies must reconcile a statutory directive that overrides a clinical classification with their evidence-based regulatory framework, increasing legal exposure and operational complexity during implementation.
Key Issues
The Core Tension
The bill forces a direct trade-off between Congress’s ability to set statutory limits on how federal agencies characterize medical conditions and the FDA’s role as a science-driven regulator responsible for assessing safety and efficacy; it resolves a policy choice (not treating pregnancy as an illness) by removing agency discretion, but in doing so it undermines the statutory and scientific processes that permit safe introduction and control of medications.
The bill’s central operational ambiguity is its undefined terms and lack of transition mechanics. "Abortion drug" is not defined, so litigants and regulators will immediately contest whether the prohibition covers drugs used in medical management of miscarriage, ectopic pregnancy therapies, or other reproductive-health medicines that can be used in both pregnancy termination and other indications. The absence of a phase-in or safety fallback (no temporary access mechanism, emergency exceptions, or alternative REMS) raises practical risks to patient care if supply chains and prescribing habits change overnight.
Legally, the retroactive nullification of FDA approvals raises multiple implementation and constitutional questions. Voiding agency actions that were lawfully granted under the FDCA could prompt challenges under separation-of-powers doctrines, the Administrative Procedure Act (for example whether Congress can retroactively void an agency decision tied to a complex administrative record), and due process or takings claims from rights-holders whose property interests (contracts, investments, market authorization) are impaired.
Moreover, by substituting a categorical legal premise for clinical judgment, the bill creates a precedent for legislating around specific scientific determinations, which could unsettle FDA’s broader regulatory methodology and invite litigation about preemption and statutory conflicts.
On the public-health side, removing FDA approval without an alternative safety regime could degrade patient safety. FDA approval and REMS structures carry specific labeling, provider training, and distribution controls designed to mitigate risk; eliminating them without replacement can increase off-label use, black-market distribution, or compel clinicians to use less-supported treatment pathways.
Finally, enforcement will be messy: the FDCA makes distribution of unapproved new drugs a violation, but the bill does not specify which federal officials must act or how industry should withdraw products—so courts, state regulators, or DOJ/FDA enforcement choices will determine immediate real-world effects.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.